A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial
Open accessThe DOI matches its Crossref record; 106 of the 107 references it cites were found in a registry or an index.
Abstract
Background: Heavy menstrual bleeding (HMB) is a common problem, yet evidence to inform decisions about initial medical treatment is limited. Objectives: To assess the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system (LNG-IUS) (Mirena ® , Bayer) compared with usual medical treatment, with exploration of women’s perspectives on treatment. Design: A pragmatic, multicentre randomised trial with an economic evaluation and a longitudinal qualitative study. Setting: Women who presented in primary care. Participants: A total of 571 women with HMB. A purposeful sample of 27 women who were randomised or ineligible owing to treatment preference participated in semistructured face-to-face interviews around 2 and 12 months after commencing treatment. Interventions: LNG-IUS or usual medical treatment (tranexamic acid, mefenamic acid, combined oestrogen–progestogen or progesterone alone). Women could subsequently swap or cease their allocated treatment. Outcome measures: The primary outcome was the patient-reported score on the Menorrhagia Multi-Attribute Scale (MMAS) assessed over a 2-year period and then again at 5 years. Secondary outcomes included general quality of life (QoL), sexual activity, surgical intervention and safety. Data were analysed using iterative constant comparison. A state transition model-based cost–utility analysis was undertaken alongside the randomised trial. Quality-adjusted life-years (QALYs) were derived from the European Quality of Life-5 Dimensions (EQ-5D) and the Short Form questionnaire-6 Dimensions (SF-6D). The intention-to-treat analyses were reported as cost per QALY gained. Uncertainty was explored by conducting both deterministic and probabilistic sensitivity analyses. Results: The MMAS total scores improved significantly in both groups at all time points, but were significantly greater for the LNG-IUS than for usual treatment [mean difference over 2 years was 13.4 points, 95% confidence interval (CI) 9.9 to 16.9 points; p < 0.001]. However, this difference between groups was reduced and no longer significant by 5 years (mean difference in scores 3.9 points, 95% CI –0.6 to 8.3 points; p = 0.09). By 5 years, only 47% of women had a LNG-IUS in place and 15% were still taking usual medical treatment. Five-year surgery rates were low, at 20%, and were similar, irrespective of initial treatments. There were no significant differences in serious adverse events between groups. Using the EQ-5D, at 2 years, the relative cost-effectiveness of the LNG-IUS compared with usual medical treatment was £1600 per QALY, which by 5 years was reduced to £114 per QALY. Using the SF-6D, usual medical treatment dominates the LNG-IUS. The qualitative findings show that women’s experiences and expectations of medical treatments for HMB vary considerably and change over time. Women had high expectations of a prompt effect from medical treatments. Conclusions: The LNG-IUS, compared with usual medical therapies, resulted in greater improvement over 2 years in women’s assessments of the effect of HMB on their daily routine, including work, social and family life, and psychological and physical well-being. At 5 years, the differences were no longer significant. A similar low proportion of women required surgical intervention in both groups. The LNG-IUS is cost-effective in both the short and medium term, using the method generally recommended by the National Institute for Health and Care Excellence. Using the alternative measures to value QoL will have a considerable impact on cost-effectiveness decisions. It will be important to explore the clinical and health-care trajectories of the ECLIPSE (clinical effectiveness and cost-effectiveness of levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia) trial participants to 10 years, by which time half of the cohort will have reached menopause. Trial registration: Current Controlled Trials ISRCTN86566246. Funding: This project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 19, No. 88. See the NIHR Journals Library website for further project information
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“When this health benefit is valued in monetary terms at the UK Department of Health's current rate of £60 000 per QALY,24 this represents a ROI of 3.16 (£60 000−£13 000/£13 000).”
From Return on investment of public health interventions: a systematic review (2017) · cites this paper as [23]
In the citing paper
“It has been estimated that investing an additional £13 000 in the English National Health Service (NHS) can achieve health benefits of one additional quality-adjusted life year (QALY).23”
From Return on investment of public health interventions: a systematic review (2017) · cites this paper as [23]
In the citing paper
“many trials struggle with recruitment and often request extensions or become at risk of closure. 14 15”
From Role of feasibility and pilot studies in randomised controlled trials: a cross-sectional study (2018) · cites this paper as [14]
In the citing paper
“The mean cost of clinical trials funded by the UK National Institute for Health and Care Research was lower but still sizeable at about £1.3m, and also with considerable variation.104”
From SPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials (2025) · cites this paper as [104]
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Grounded theory research: Procedures, canons, and evaluative criteria
Corbin, J. M., & Strauss, A. (1990) · Qualitative Sociology · doi:10.1007/bf00988593 · Cited by 11,133
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003) · Medical Care · doi:10.1097/01.mlr.0000062554.74615.4c · Cited by 4,700 · cited 2×
“5 SD, which is the minimum clinically important difference identified in a systematic review of studies reporting such data for health-related QoL measures.(79) A 13.”
BackgroundScale Development: Theory and Applications.
Xie, Y., & DeVellis, R. F. (1992) · Contemporary Sociology · doi:10.2307/2075704 · Cited by 3,635 · cited 1×
“9, suggesting that the items are all measuring aspects of the same construct.(68) Evidence of the homogeneity of the MMAS was also provided by the item total correlations (the correlation between each item and the total score minus that item) which range between 0.”
BackgroundDecision Modelling For Health Economic Evaluation
Briggs, A., Claxton, K., & Sculpher, M. (2006) · doi:10.1093/oso/9780198526629.001.0001 · Cited by 3,153
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
The SF36 health survey questionnaire: an outcome measure suitable for routine use within the NHS?
Garratt, A. M., Ruta, D. A., Abdalla, M. I., Buckingham, J. K., & Russell, I. T. (1993) · BMJ · doi:10.1136/bmj.306.6890.1440 · Cited by 1,141
Strategy for intention to treat analysis in randomised trials with missing outcome data
White, I. R., Horton, N. J., Carpenter, J., statistics, R. I. M. A. S., & Pocock, S. J. (2011) · BMJ · doi:10.1136/bmj.d40 · Cited by 849 · cited 1×
“A number of sensitivity analyses were performed on the primary outcome to test the robustness of the results.(77,78) Analyses were performed excluding data received subsequent to a crossover to the alternative treatment group and also once study treatment was ceased altogether.”
MethodLinear mixed models for longitudinal data
(2000) · Springer Series in Statistics · doi:10.1007/b98969 · Cited by 818
A comparison of the EQ‐5D and SF‐6D across seven patient groups
Brazier, J., Roberts, J., Tsuchiya, A., & Busschbach, J. (2004) · Health Economics · doi:10.1002/hec.866 · Cited by 797 · cited 1×
“However, at the inception of this trial in 2002, the use of SF-6D was in its infancy and still being developed.(101) It was included in the current study as a methodological component.”
MethodLiu, Z., Doan, Q. V., Blumenthal, P., & Dubois, R. W. (2007) · Value in Health · doi:10.1111/j.1524-4733.2007.00168.x · Cited by 397
Missing.... presumed at random: cost‐analysis of incomplete data
Briggs, A., Clark, T., Wolstenholme, J., & Clarke, P. (2003) · Health Economics · doi:10.1002/hec.766 · Cited by 346 · cited 1×
“Where a transition between states is possible, but did not occur in the trial data, a value of 1 is added to all such transitions to enable the Dirichlet distribution to be assigned and to compensate for not observing the transition in the data.(112) In Table 12 it can be seen that some distributions are fixed at the…”
BackgroundHurskainen, R., Teperi, J., Rissanen, P., Aalto, A.-M., Grenman, S., Kivelä, A., Kujansuu, E., Vuorma, S., Yliskoski, M., & Paavonen, J. (2004) · JAMA · doi:10.1001/jama.291.12.1456 · Cited by 332 · cited 3×
“Another primary study has shown the LNG-IUS to be cost-effective, but the comparator was hysterectomy and the study is considered to have methodological flaws.(58,103) Other studies have compared alternative treatments using model-based analyses and secondary data from reviews,(1,113,114) although the studies typicall…”
BackgroundMethodResultThe Sexual Activity Questionnaire: A measure of women's sexual functioning
Thirlaway, K., Fallowfield, L., & Cuzick, J. (1996) · Quality of Life Research · doi:10.1007/bf00435972 · Cited by 309 · cited 1×
“The validated SAQ measures pleasure [with scores ranging from 0 (lowest level) to 18 (highest level)], discomfort [with scores ranging from 0 (greatest) to 6 (none)] and frequency (assessed relative to perceived usual activity as an ordinal response).(73) Scores were obtained before randomisation and by mail at 6 mont…”
BackgroundHurskainen, R., Teperi, J., Rissanen, P., Aalto, A.-M., Grenman, S., Kivelä, A., Kujansuu, E., Vuorma, S., Yliskoski, M., & Paavonen, J. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03615-1 · Cited by 299 · cited 3×
“Clinical effectiveness of the levonorgestrel-releasing intrauterine system compared with surgery Prior to the start of the ECLIPSE trial, there were six RCTs comparing the effectiveness of the LNG-IUS with surgery, two using first-generation ablation methods,(29,30) three comparing the LNG-IUS with second-generation t…”
MethodBritish National Formulary: BNF
Press, P. (2015) · doi:10.18578/bnf.147942626 · Cited by 269
Irvine, G. A., Campbell‐Brown, M. B., Lumsden, M. A., Heikkilä, A., Walker, J. J., & Cameron, I. T. (1998) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1998.tb10172.x · Cited by 268
Lähteenmäki, P., Prentice, A., Haukkamaa, M., Puolakka, J., Riikonen, U., Sainio, S., Suvisaari, J., & Nilsson, C. G. (1998) · BMJ · doi:10.1136/bmj.316.7138.1122 · Cited by 245 · cited 2×
“The lack of blinding and the control group remaining on an unsatisfactory treatment is likely to have influenced the women’s attitude to treatment and subjective assessment of QoL, therefore, is inherently biased against existing therapy.(31) Clinical effectiveness of the levonorgestrel-releasing intrauterine system c…”
MethodWarner, P. E., Critchley, H. O. D., Lumsden, M. A., Campbell-Brown, M., Douglas, A., & Murray, G. D. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2003.11.015 · Cited by 242
CROSIGNANI, P., VERCELLINI, P., MOSCONI, P., OLDANI, S., CORTESI, I., & DEGIORGI, O. (1997) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(97)00226-3 · Cited by 229 · cited 1×
“No difference in the rates of amenorrhoea or satisfaction rates were seen compared with endometrial ablation, although menstrual blood loss was reduced to a greater extent with ablation.(29,48) In a subsequent Cochrane review of medical versus surgical treatments for HMB,(51) an additional six trials, four comparing t…”
ResultMilsom, I., Andersson, K., Andersch, B., & Rybo, G. (1991) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(11)90533-x · Cited by 226 · cited 1×
“Initial concerns regarding a potential increase in adverse thrombogenic events has been refuted by long-term studies showing no excess risk.(20) Mefenamic acid Mefenamic acid is a non-steroidal anti-inflammatory drug (NSAID), which can reduce the formation of prostaglandins, implicated in the abnormal clotting in the…”
BackgroundModelling SF-6D health state preference data using a nonparametric Bayesian method
Kharroubi, S. A., Brazier, J. E., Roberts, J., & O’Hagan, A. (2007) · Journal of Health Economics · doi:10.1016/j.jhealeco.2006.09.002 · Cited by 215 · cited 1×
“The SF-36 was converted into SF-6D using the algorithm.(106) Utility values for each state in the model were calculated by averaging the EQ-5D or SF-6D values for each woman in the given state at any given time.”
MethodTranexamic Acid: A Review of its Use in the Management of Menorrhagia
Wellington, K., & Wagstaff, A. J. (2003) · Drugs · doi:10.2165/00003495-200363130-00008 · Cited by 212 · cited 1×
“There was sufficient evidence in three systematic reviews for NICE to conclude that a tranexamic acid causes a clinically significant reduction in menstrual blood loss for women with HMB, ranging from 29% to 58% in studies lasting up to 1 year, although long-term data are missing.(11,21,27,35) NSAIDs (mefenamic acid o…”
BackgroundPsychiatric disorder and gynaecological symptoms in middle aged women: a community survey.
Gath, D., Osborn, M., Bungay, G., Iles, S., Day, A., Bond, A., & Passingham, C. (1987) · BMJ · doi:10.1136/bmj.294.6566.213 · Cited by 206 · cited 1×
“Another survey found that while 22% of menstruating women over 35 years considered their periods heavy and interfering with their lives, only 7% had consulted their GP in the preceding 6 months.(13) Despite the many factors influencing women’s decisions not to seek help,(14) the number and cost of consultations and tr…”
BackgroundStewart, A., Cummins, C., Gold, L. H., Jordan, R., & Phillips, W. (2001) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2001.00020.x · Cited by 199 · cited 4×
“An early systematic review highlighted the lack of evidence on the relative benefits of the LNG-IUS compared with medical treatment and recommended large pragmatic trials.(28) This was reiterated by the NICE guidelines.”
MethodResultInfluentialSculpher, M. J., Dwyer, N., Byford, S., & Stirrat, G. M. (1996) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1996.tb09666.x · Cited by 181 · cited 1×
“issues relevant to patients’ expectations and concerns) and items for measurement properties (including reliability, responsiveness, criterion or construct validity and acceptability).(60)”
BackgroundAndronis, L., Barton, P. M., & Bryan, S. (2009) · Health Technology Assessment · doi:10.3310/hta13290 · Cited by 175 · cited 1×
“This is repeated 1000 times and the range of incremental cost and QALY results for the LNG-IUS and usual medical treatment are presented on the cost-effectiveness plane.(111) These 1000 values were used to construct a cost-effectiveness acceptability curve (CEAC) to illustrate the probability of the LNG-IUS being more…”
MethodSelf-citationProgesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding
Lethaby, A., Cooke, I., & Rees, M. C. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002126.pub2 · Cited by 175
Fraser, I. S., & McCarron, G. (1991) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/j.1479-828x.1991.tb02769.x · Cited by 173
Levonorgestrel Intrauterine System versus Medical Therapy for Menorrhagia
Gupta, J., Kai, J., Middleton, L., Pattison, H., Gray, R., & Daniels, J. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1204724 · Cited by 172 · cited 4×
“Methods Sampling A purposeful sample was selected from women approached for inclusion in the ECLIPSE trial of the effectiveness of medical treatments for HMB in primary care.(93) They had consulted their GP about HMB (lasting three or more consecutive cycles).”
MethodResultInfluentialSelf-citationMiddleton, L. J., Champaneria, R., Daniels, J. P., Bhattacharya, S., Cooper, K. G., Hilken, N. H., O'Donovan, P., Gannon, M., Gray, R., Khan, K. S., et al. (2010) · BMJ · doi:10.1136/bmj.c3929 · Cited by 167 · cited 1×
“This review was extended by obtaining individual patient data in order to be able to standardise outcome data, such as satisfaction or, the corollary, dissatisfaction.(57) Rates of dissatisfaction with the LNG-IUS and non-hysteroscopic endometrial destruction were similar (18% vs.”
MethodSelf-citationSurgery versus medical therapy for heavy menstrual bleeding
Marjoribanks, J., Lethaby, A. E., & Farquhar, C. M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003855.pub2 · Cited by 161
Levonorgestrel-Releasing Intrauterine System or Medroxyprogesterone for Heavy Menstrual Bleeding
Kaunitz, A. M., Bissonnette, F., MONTEIRO, I. M. U., Lukkari‐Lax, E., Muysers, C., & Jensen, J. T. (2010) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e3181ec622b · Cited by 145
Effect of Hysterectomy vs Medical Treatment on Health-Related Quality of Life and Sexual Functioning
Kuppermann, M., Varner, R. E., Summitt, R. L., Learman, L. A., Ireland, C. C., Vittinghoff, E., Stewart, A. L., Lin, F., Richter, H. E., Showstack, J. A., et al. (2004) · JAMA · doi:10.1001/jama.291.12.1447 · Cited by 144
Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding
Lethaby, A. E., Duckitt, K., & Farquhar, C. M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000400.pub3 · Cited by 131
Menorrhagia II: is the 80-mL blood loss criterion useful in management of complaint of menorrhagia?
Warner, P., Critchley, H., Lumsden, M. A., Campbell‐Brown, M., Douglas, A., & Murray, G. D. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2003.11.016 · Cited by 130 · cited 3×
“Unpredictable irregular bleeding with the LNG-IUS was more problematic than the volume of blood loss for women in this study, owing to its impact on their established behavioural coping mechanisms for HMB. Women viewed standard treatment options, such as oral tranexamic acid, as a short-term measure, and one that was…”
BackgroundRoberts, T. E., Tsourapas, A., Middleton, L. J., Champaneria, R., Daniels, J. P., Cooper, K. G., Bhattacharya, S., & Barton, P. M. (2011) · BMJ · doi:10.1136/bmj.d2202 · Cited by 128 · cited 5×
“Data on the weighted likelihood of surgery undertaken were taken from a previous study.(103) It is assumed that if a woman in the trial has endometrial ablation then it will be for her first ablation and we apply the cost for first-line endometrial ablation techniques.”
BackgroundMethodResultInfluentialSelf-citationSuvisaari, J. V. J., & Lähteenmäki, P. (1996) · Contraception · doi:10.1016/s0010-7824(96)00189-8 · Cited by 123 · cited 1×
“The main disadvantage of the LNG-IUS is the disruption to the menstrual cycle, particularly in the first 6 months, with the number of bleeding and spotting days increasing to a median of 18 days and the cycle becoming irregular in approximately 20% of women, before reducing in duration and severity.(25) The proportion…”
BackgroundReid, P., & Virtanen‐Kari, S. (2005) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2005.00642.x · Cited by 113 · cited 1×
“The ECLIPSE study is the world’s largest trial comparing medical treatments for HMB over the short to medium term, rather than 6 or 12 months, as in previous studies.(24,33) It had a multicentre design and included patients ethnically representative of the UK population, with relatively low rates of loss to follow-up…”
MethodCritchley, H., Warner, P., Lee, A., Brechin, S., Guise, J., & Graham, B. (2004) · Health Technology Assessment · doi:10.3310/hta8340 · Cited by 110 · cited 1×
“The majority of women with HMB have no pathology that can be attributed as the cause of their symptoms, while approximately 30% will have uterine fibroids and 10% uterine polyps, with malignant causes being rare in the pre-menopausal population.(7)”
BackgroundShaw, R. W., Brickley, M. R., Evans, L., & Edwards, M. J. (1998) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1998.tb09968.x · Cited by 108 · cited 8×
“The greater improvement with the LNG-IUS over the first 2 years was seen despite 36% of women having had the system removed, generally owing to the lack of effectiveness or to irregular prolonged bleeding, which are well-recognised reasons for discontinuing the LNG-IUS.(61,66) There were higher rates of discontinuatio…”
BackgroundMethodInfluentialShabaan, M. M., Zakherah, M. S., El‐Nashar, S. A., & Sayed, G. H. (2010) · Contraception · doi:10.1016/j.contraception.2010.06.011 · Cited by 106
Patients' Preferences and General Practitioners' Decisions in the Treatment of Menstrual Disorders
Coulter, A., Peto, V., & Doll, H. (1994) · Family Practice · doi:10.1093/fampra/11.1.67 · Cited by 105 · cited 1×
“Women who seek treatment for HMB can have predetermined expectations and preferences for a treatment influenced by diverse factors, such as employment status as well as severity of symptoms.(90,91) They may also reflect contraceptive preferences, attitudes to hormonal treatments, ‘the pill’ or ‘coil’ and the presence…”
BackgroundCoulter, A., Kelland, J., Peto, V., & REES, M. C. P. (1995) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462300008679 · Cited by 103 · cited 1×
“There was sufficient evidence in three systematic reviews for NICE to conclude that a tranexamic acid causes a clinically significant reduction in menstrual blood loss for women with HMB, ranging from 29% to 58% in studies lasting up to 1 year, although long-term data are missing.(11,21,27,35) NSAIDs (mefenamic acid o…”
BackgroundInpatient hospitalization for gynecologic disorders in the United States
Whiteman, M. K., Kuklina, E. V., Jamieson, D. J., Hillis, S. D., & Marchbanks, P. A. (2010) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2009.12.013 · Cited by 101 · cited 1×
“Heavy menstrual bleeding accounts for 19% of gynaecologist office consultations in the USA(10) and 20% in the UK,(11) and each year around 6% of women in the USA consult their general practitioner (GP).(12) Another survey found that while 22% of menstruating women over 35 years considered their periods heavy and inter…”
BackgroundThe effects of mefenamic acid and norethisterone on measured menstrual blood loss.
Cameron, I. T., Haining, R., Lumsden, M. A., Thomas, V. R., & Smith, S. K. (1990) · PubMed · Cited by 93
Santer, M., Wyke, S., & Warner, P. (2007) · BMC Women s Health · doi:10.1186/1472-6874-7-8 · Cited by 91 · cited 3×
“Unpredictable irregular bleeding with the LNG-IUS was more problematic than the volume of blood loss for women in this study, owing to its impact on their established behavioural coping mechanisms for HMB. Women viewed standard treatment options, such as oral tranexamic acid, as a short-term measure, and one that was…”
BackgroundPatterns of ambulatory care use for gynecologic conditions: A national study
Nicholson, W. K., Ellison, S. A., Grason, H. A., & Powe, N. R. (2001) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2001.111795 · Cited by 90
Menstrual symptoms: the importance of social factors in women's experiences.
O’Flynn, N. (2006) · PubMed Central · Cited by 90
Rauramo, I., Elo, I., & Istre, O. (2004) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000143824.16435.91 · Cited by 90 · cited 1×
“We are aware of few trials in this field reporting outcomes at 5 years.(38,58) The current data have allowed an accurate estimate of the 5-year retention rate of the LNG-IUS – at around half of those initially allocated to this treatment at randomisation.”
BackgroundDeveloping Multiattribute Health Indexes
Boyle, M. H., & Torrance, G. W. (1984) · Medical Care · doi:10.1097/00005650-198411000-00007 · Cited by 87 · cited 1×
“This was developed in collaboration with women with HMB using a multi-attribute utility method.(64) It was decided that this scale should be the principal outcome measure for the ECLIPSE trial.”
MethodOral contraceptive pill for heavy menstrual bleeding
Farquhar, C. M., & Brown, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000154.pub2 · Cited by 83 · cited 1×
“Combined oral contraceptive pill Combined oral contraceptives of any formulation reduce the thickness of the endometrium and inhibit ovulation, with a resultant reduction in menstrual blood loss of 43%.(22) There is no evidence of any relative difference with other medical treatments.”
BackgroundBusfield, R., Farquhar, C. M., Sowter, M. C., Lethaby, A. E., Sprecher, M., Yu, Y., Sadler, L., Brown, P., & Johnson, N. (2006) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2006.00863.x · Cited by 83 · cited 1×
“This proportion is consistent with the proportions of women who discontinued the LNG-IUS treatment in smaller trials that compared it with hysterectomy(50) (31% of 117 women at 12 months) or with endometrial ablation (28% of 105 women at 2 years).(30,49,81) In subgroup analyses, the LNG-IUS appeared to be less benefic…”
ResultEndrikat, J., Shapiro, H. M., Lukkari‐Lax, E., Kunz, M., Schmidt, W., & Fortier, M. P. (2009) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)34151-2 · Cited by 80
Willingness-to-pay for colorectal cancer screening
Frew, E. J., Wolstenholme, J. L., & Whynes, D. K. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00200-3 · Cited by 78
Quality of life instruments in studies of menorrhagia: a systematic review
Clark, T. J., Khan, K. S., Foon, R., Pattison, H. M., Bryan, S., & Gupta, J. K. (2002) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/s0301-2115(02)00076-3 · Cited by 77 · cited 1×
“Clark et al.(59) suggest that, in order to ensure that a trial has an appropriate set of outcome measures, a condition-specific instrument could be used in combination with a generic instrument.”
Self-citationReid, P. (2006) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2006.08.008 · Cited by 77 · cited 1×
“In 2004–5, there were 7179 hysterectomies and 9701 endometrial ablations performed; compared with 1989–90 this represents a 69% decrease and an 11-fold increase in the number of procedures for HMB, respectively.(15) Rates of surgical procedures for HMB are 17.”
MethodBarrington, J. W., Arunkalaivanan, A. S., & Abdel‐Fattah, M. (2003) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/s0301-2115(02)00408-6 · Cited by 71
Systematic Review and Empirical Comparison of Contemporaneous EQ-5D and SF-6D Group Mean Scores
Whitehurst, D. G. T., Bryan, S., & Lewis, M. (2011) · Medical Decision Making · doi:10.1177/0272989x11421529 · Cited by 70
Clinical associations with objective menstrual blood volume
HIGHAM, J. M., & Shaw, R. W. (1999) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/s0301-2115(98)00224-3 · Cited by 70 · cited 5×
“Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK. v However, using the SF-36 to produce utility values, usual…”
InfluentialCameron, I. T., Leask, R., KELLY, R. W., & Baird, D. T. (1987) · Prostaglandins · doi:10.1016/0090-6980(87)90267-x · Cited by 69
Garside, R., Britten, N., & Stein, K. (2008) · Journal of Advanced Nursing · doi:10.1111/j.1365-2648.2008.04750.x · Cited by 69
Menorrhagia in general practice — disease or illness
O’Flynn, N., & Britten, N. (2000) · Social Science & Medicine · doi:10.1016/s0277-9536(99)00318-4 · Cited by 67 · cited 3×
“This finding is consistent with other work.(95,96) Going beyond reduction in volume of blood loss alone, measures of QoL are now becoming more widely used to determine treatment efficacy.”
BackgroundMethodResultGarside, R., Stein, K., Wyatt, K. M., Round, A., & Price, A. (2004) · Health Technology Assessment · doi:10.3310/hta8030 · Cited by 64
Brazier, J. E., Kolotkin, R. L., Crosby, R. D., & Williams, G. R. (2004) · Value in Health · doi:10.1111/j.1524-4733.2004.74012.x · Cited by 63
Soysal, M. E., Soysal, S., & Özer, S. (2002) · Zentralblatt für Gynäkologie · doi:10.1055/s-2002-32434 · Cited by 63 · cited 5×
“Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK. v However, using the SF-36 to produce utility values, usual…”
ResultInfluentialKittelsen, N., & Istre, O. (1998) · Gynaecological Endoscopy · doi:10.1046/j.1365-2508.1998.00165.x · Cited by 62 · cited 1×
“This proportion is consistent with the proportions of women who discontinued the LNG-IUS treatment in smaller trials that compared it with hysterectomy(50) (31% of 117 women at 12 months) or with endometrial ablation (28% of 105 women at 2 years).(30,49,81) In subgroup analyses, the LNG-IUS appeared to be less benefic…”
ResultShaw, R. W., Symonds, I., Tamizian, O., CHAPLAIN, J., & Mukhopadhyay, S. (2007) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/j.1479-828x.2007.00747.x · Cited by 56
Nilsson, C. G., Luukkainen, T., Dı́az, J., & Allonen, H. O. (1982) · Contraception · doi:10.1016/0010-7824(82)90092-0 · Cited by 55 · cited 1×
“The proportion of women who are amenorrhoeic a year following insertion has been reported at around 12%.(26,27)”
BackgroundProtheroe, J., Bower, P., Chew-Graham, C. A., Peters, T. J., & Fahey, T. P. (2007) · Medical Decision Making · doi:10.1177/0272989x07306785 · Cited by 55 · cited 1×
“high degree of reliability and internal consistency,(71) has good content and construct validity,(61,71) is responsive(65,72) and is acceptable to respondents.(61,65,71,72) Secondary outcome measures included general health-related QoL and sexual activity.”
BackgroundGuidelines for the Management of Abnormal Uterine Bleeding
Committees, R. E. I. (2001) · Journal SOGC · doi:10.1016/s0849-5831(16)31463-x · Cited by 54
Pattison, H. M., DANIELS, J. P., Kai, J., & Gupta, J. (2011) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2011.03057.x · Cited by 50
Self-citationSculpher, M. (1998) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462300012277 · Cited by 50
Development and validation of the menorrhagia outcomes questionnaire
Lamping, D. L., Rowe, P. A., Clarke, A., Black, N. A., & Lessof, L. (1998) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1998.tb10209.x · Cited by 49
Stead, M. L., Crocombe, W. D., Fallowfield, L. J., Selby, P. J., Perren, T. J., Garry, R., & Brown, J. M. (1999) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1999.tb08084.x · Cited by 48 · cited 1×
“The Sexual Activity Questionnaire The Sexual Activity Questionnaire (SAQ) was developed as a self-report questionnaire, for use in gynaecological clinical trials, which would be quick to complete and acceptable to the majority of women.(67) Three dimensions of perceptions of sexual activity are measured: pleasure, dis…”
MethodSekharan, P. (2005) · Jaypee Brothers Medical Publishers (P) Ltd. eBooks · doi:10.5005/jp/books/10276_8 · Cited by 46
Levonorgestrel-releasing Intrauterine System – The discontinuing story
Ewies, A. A. A. (2009) · Gynecological Endocrinology · doi:10.1080/09513590903159656 · Cited by 44 · cited 4×
“Of the 228 women who discontinued usual medical treatment by 5 years, 43% switched to the LNG-IUS.”
ResultInfluentialDaily Menstrual Blood Loss and Quality of Life in Women with Heavy Menstrual Bleeding
Lukes, A. S., Baker, J., Eder, S. E., & Adomako, T. L. (2012) · Women s Health · doi:10.2217/whe.12.36 · Cited by 44 · cited 1×
“Higher volume of daily menstrual blood loss has been correlated with limitations in functioning and social activities.(99) Women in this study were as concerned with menstrual pain and psychological distress affecting their health and QoL as with HMB itself.”
BackgroundHost Factors That Influence the Duration of Menstrual Bleeding
Harlow, S. D., & Campbell, B. (1994) · Epidemiology · doi:10.1097/00001648-199405000-00017 · Cited by 43 · cited 1×
“Objective measures are inconvenient and impractical, and indirect measures of menstrual blood loss, such as pictorial diaries, are not consistently accurate and these too fail to reflect women’s experience of what is burdensome for them.(8) A full blood count is recommended by the NICE guidelines,(1) but serum ferriti…”
BackgroundTam, W. H., Yuen, P. M., Ng, D. P. S., Leung, P. L., Lok, I. H., & Rogers, M. S. (2006) · Gynecologic and Obstetric Investigation · doi:10.1159/000092660 · Cited by 40
You, J. H. S., Sahota, D. S., & MoYuen, P. (2006) · Human Reproduction · doi:10.1093/humrep/del088 · Cited by 38 · cited 1×
“The remaining study suggested that hysterectomy was the optimal intervention, but the authors acknowledged that insufficient published data on the effectiveness of the LNG-IUS were available at the time.(114) Although the LNG-IUS is shown to be cost-effective against surgical interventions in these studies, it does no…”
BackgroundEstimating a meaningful reduction in menstrual blood loss for women with heavy menstrual bleeding
Lukes, A. S., Muse, K. N., Richter, H. E., Moore, K. A., & Patrick, D. L. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.526098 · Cited by 37
Cromwell, D. A., Mahmood, T. A., Templeton, A., & van der Meulen, J. (2009) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2009.02284.x · Cited by 35
de Souza, S. S., Camargos, A. F., Rezende, C. P., Pereira, F. D. A. N., Araújo, C. A. A., & Filho, A. L. D. S. (2009) · Contraception · doi:10.1016/j.contraception.2009.09.012 · Cited by 35
Menorrhagia: women’s perceptions of this condition and its treatment
Chapple, A. (1999) · Journal of Advanced Nursing · doi:10.1046/j.1365-2648.1999.01038.x · Cited by 35 · cited 1×
“Heavy menstrual bleeding and other changes in menstrual experience may affect many aspects of women’s health, well-being and social functioning.(83) Although there is existing evidence comparing the effectiveness of various treatments in reducing menstrual blood loss, we know less about women’s experiences or expectat…”
BackgroundWhy women consult with increased vaginal bleeding: a case-control study.
Shapley, M., Jordan, K. P., & Croft, P. R. (2002) · PubMed · Cited by 34
Endrikat, J., Vilos, G. A., Muysers, C., Fortier, M. P., Solomayer, E. F., & Lukkari‐Lax, E. (2011) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-011-1902-1 · Cited by 32 · cited 2×
“In addition, previous trials have focused on the reduction of menstrual blood loss, which does not reflect the full effect of HMB on women’s lives.(28,45) In contrast, our primary outcome measure was the patient-reported, psychometrically valid, condition-specific MMAS, which better reflects women’s personal experienc…”
MethodResultDiagnosing menstrual disorders: a qualitative study of the approach of primary care professionals.
O’Flynn, N., & Britten, N. (2004) · PubMed · Cited by 30
Risk-Benefit Assessment of Drugs Used for the Treatment of Menstrual Disorders
HIGHAM, J. M., & Shaw, R. W. (1991) · Drug Safety · doi:10.2165/00002018-199106030-00004 · Cited by 30 · cited 1×
“Tranexamic acid Tranexamic acid is a plasminogen activator inhibitor that exerts an antifibrinolytic effect on the endometrium, reducing menstrual blood loss by 50%.(19) It is taken in high doses, of up to 1 g four times per day, during the first 5 days of the menstrual cycle.”
BackgroundCorrelates of women’s preferences for treatment of heavy menstrual bleeding
Vuorma, S., Teperi, J., Hurskainen, R., Aalto, A., Rissanen, P., & Kujansuu, E. (2003) · Patient Education and Counseling · doi:10.1016/s0738-3991(02)00069-1 · Cited by 27 · cited 1×
“Women who seek treatment for HMB can have predetermined expectations and preferences for a treatment influenced by diverse factors, such as employment status as well as severity of symptoms.(90,91) They may also reflect contraceptive preferences, attitudes to hormonal treatments, ‘the pill’ or ‘coil’ and the presence…”
BackgroundBrooks, R. (1996) · Critical Care Medicine · doi:10.1097/00003246-199610000-00027 · Cited by 22
Coulter, A., Long, A., Kelland, J., O’Meara, S., Sculpher, M. J., Song, F., & Sheldon, T. (1995) · BMJ Quality & Safety · doi:10.1136/qshc.4.3.218 · Cited by 22
Shapley, M., Jordan, K. P., & Croft, P. R. (2003) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1046/j.1471-0528.2003.02458.x · Cited by 21
A new menstrual pictogram for use with feminine products that contain superabsorbent polymers
Magnay, J. L., Nevatte, T. M., Seitz, C., & O’Brien, S. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.08.028 · Cited by 21
Iron deficiency anaemia in women of south Asian descent: A qualitative study
Chapple, A. (1998) · Ethnicity and Health · doi:10.1080/13557858.1998.9961862 · Cited by 21 · cited 1×
“However, others have found long-term use of tranexamic acid to be well tolerated over a 15-month timeframe, although emergent adverse effects such as headaches, menstrual and back pain were commonly reported.(86) Implications for practice These qualitative findings suggest that discussion with women about medical trea…”
BackgroundHabiba, M. A., Julian, S., Taub, N. A., Clark, M., Rashid, A., Baker, R., & Szczepura, A. K. (2009) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2009.09.021 · Cited by 21 · cited 5×
“The results provide unique and valuable practical information for women and primary care practitioners when considering choice of, and what to expect from, medical treatments for HMB.”
BackgroundMethodResultInfluentialManagement of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection
Malak, K. A., & Shawki, O. (2006) · Gynecological Surgery · doi:10.1007/s10397-006-0234-9 · Cited by 21
Albers, J. R., Hull, S. K., & Wesley, R. M. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-2958-8.50025-1 · Cited by 19
Increased vaginal bleeding: the reasons women give for consulting primary care
Shapley, M., Jordan, K. P., & Croft, P. (2003) · Journal of Obstetrics and Gynaecology · doi:10.1080/0144361021000043245 · Cited by 17 · cited 1×
“Women with psychological distress appear more likely to report heavy periods(13,87) and the effect of menstrual bleeding on mood may influence a woman’s ability to continue life as normal.(88) Similarly, other menstrual symptoms such as pain, mood changes and irregular bleeding may influence perceptions of the severit…”
BackgroundChapple, A., Ling, M., & May, C. R. (1998) · Ethnicity and Health · doi:10.1080/13557858.1998.9961851 · Cited by 15
Lete, I., Cuesta, M. D. C., Marín, J. M., Martínez, M. Á. H., Bermejo, A., & Arina, R. (2010) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2010.07.040 · Cited by 12
Shapley, M., Jordan, K. P., & Croft, P. R. (2007) · Family Practice · doi:10.1093/fampra/cmm068 · Cited by 12 · cited 1×
“A UK survey of women aged 18–54 years indicated an annual community incidence HMB of 25% and prevalence of 52%, with a slight increase with increasing age.(9) Heavy menstrual bleeding accounts for 19% of gynaecologist office consultations in the USA(10) and 20% in the UK,(11) and each year around 6% of women in the US…”
BackgroundLähteenmäki, P. (1990) · BMJ · doi:10.1136/bmj.301.6746.291 · Cited by 10
Heavy menstrual bleeding: delivering patient-centred care
Santer, M. (2008) · British Journal of General Practice · doi:10.3399/bjgp08x277258 · Cited by 9
An assessment of economic measures used in menorrhagia: A systematic review
Sanghera, S., Frew, E. J., Kai, J., Gupta, J. K., & Roberts, T. E. (2013) · Social Science & Medicine · doi:10.1016/j.socscimed.2013.09.016 · Cited by 9 · cited 4×
“A different approach that Sanghera et al.(69) explored in their review is willingness to pay (WTP).”
BackgroundMethodInfluentialSelf-citation
Research works printed but not linked: 12
- National Institute for Health and Care Excellence, 2007, Heavy Menstrual Bleeding: Guideline CG44
- Royal College of Obstetrics and Gynaecology (RCOG), 1998, The Initial Management of Menorrhagia – Evidence-Based Clinical Guidelines No. 1
- Joint Formulary Committee, 2011, British National Formulary
- Gheit, 2009, Bleeding patterns associated with progestin-only contraceptives: a prospective controlled trial comparing Mirena versus progestin only pill, Middle East Fertil Soc J, 14, 216
- Kari, 2005, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of Mirena to a Three-Month Administration of Danazol Followed by a 3-Month Observation Period in Women Aged over 30 with Functional Menorrhagia
- Muenzen, 2009, A multicenter, randomized, open label, parallel group, active control study to evaluate the efficacy and safety of LNG IUS (Mirena) as compared to medroxyprogesterone acetate during 6 cycles of treatment in patients with idiopathic menorrhagia, BSP Report
- National Institute for Health and Care Excellence, 2013, Guide to the Methods of Technology Appraisal
- Cohen, 1977, Statistical Power Analysis for the Behavioural Sciences
- Shaw, 2007, Randomised comparative trial of thermal balloon ablation and levonorgestrel intrauterine system in patients with idiopathic menorrhagia, Aust N Z J Obstet Gynaecol, 47, 335, 10.1111/j.1479-828X.2007.00747.x · DOI
- Belevantsev, Model of transition from anodization to microarc stage, Izv Sib Otd an Khim, 6, 73
- Curtis, 2012, Unit Costs of Health and Social Care 2011
- National Institute for Health and Care Excellence, 2008, Guide to the Methods of Technology Appraisal
Cited by
Kusumoto, F. M., Schoenfeld, M. H., Barrett, C., Edgerton, J. R., Ellenbogen, K. A., Gold, M. R., Goldschlager, N. F., Hamilton, R. M., Joglar, J. A., Kim, R. J., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.044 · Cited by 1,008
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00214-2017 · Cited by 881
Schünemann, H. J., Cushman, M., Burnett, A. E., Kahn, S. R., Beyer-Westendorf, J., Spencer, F. A., Rezende, S. M., Zakai, N. A., Bauer, K. A., Dentali, F., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018022954 · Cited by 819
Davenport, M. H., Ruchat, S.-M., Poitras, V. J., Jaramillo Garcia, A., Gray, C. E., Barrowman, N., Skow, R. J., Meah, V. L., Riske, L., Sobierajski, F., et al. (2018) · British Journal of Sports Medicine · doi:10.1136/bjsports-2018-099355 · Cited by 579
Witt, D. M., Nieuwlaat, R., Clark, N. P., Ansell, J., Holbrook, A., Skov, J., Shehab, N., Mock, J., Myers, T., Dentali, F., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018024893 · Cited by 511
Metadata
- Authors
- Gupta, J. K., Daniels, J. P., Middleton, L. J., Pattison, H. M., Prileszky, G., Roberts, T. E., Sanghera, S., Barton, P., Gray, R., Kai, J., & on behalf of the ECLIPSE Collaborative Group
- Affiliations
- Birmingham Women's Hospital (GB)
- University of Birmingham (GB)
- Aston University (GB)
- University of Nottingham (GB)
- University of Oxford (GB)
- Corresponding author
- Daniels, Jane P
- ORCID
- Venue
- Health Technology Assessment
- Published
- 2015-10
- Volume
- 19
- Issue
- 88
- Pages
- 1-118
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- PMC
- PMC4781345
- OpenAlex
- W2152498789
- Cited by
- 399
- References
- 107
- Citations by year
- 2026: 13 · 2025: 26 · 2024: 25 · 2023: 28 · 2022: 32 · 2021: 53 · 2020: 50 · 2019: 44 · 2018: 48 · 2017: 49 · 2016: 28 · 2015: 3
- FWCI
- 45.25
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Health Technology Assessment (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Repository@Nottingham (University of Nottingham) (publishedVersion, other-oa)
- Explore Bristol Research (publishedVersion)
- Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Nottingham ePrints (University of Nottingham) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Bristol Research (University of Bristol) (submittedVersion)
- Funders
- Health Technology Assessment programme (02/06/02)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Menstrual Health and Disorders
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- levonorgestrel-releasing intrauterine system, menorrhagia, primary care, cost-effectiveness, quality of life, patient-reported outcomes, tranexamic acid, mefenamic acid
- MeSH terms
- Antifibrinolytic Agents, Contraceptive Agents, Female, Cost-Benefit Analysis, Female, Humans, Intrauterine Devices, Medicated, Menorrhagia, Primary Health Care, Surveys and Questionnaires, Technology Assessment, Biomedical, Tranexamic Acid, Treatment Outcome, Levonorgestrel, Quality-Adjusted Life Years
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.